aTyr Pharma, Inc. announced that the United States Adopted Names (USAN) Council and the World Health Organization's (WHO) International Nonproprietary Name (INN) Expert Committee have selected the nonproprietary name efzofitimod for ATYR1923, a novel immunomodulator targeting neuropilin-2 (NRP2), in clinical development for pulmonary sarcoidosis, a major form of interstitial lung disease. The USAN Council and WHO are responsible for selecting simple, informative and unique nonproprietary (generic) drug names. Going forward, aTyr will use efzofitimod in place of ATYR1923.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 USD | -5.80% | +7.14% | +38.30% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.30% | 143M | |
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |
- Stock Market
- Equities
- LIFE Stock
- News aTyr Pharma, Inc.
- ATyr Pharma, Inc. Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name